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1. Introduction 
Management of hypoglycemia in children and adults depends on many factors. The most 
important point of view is the level of hypoglycemia and the relevance of clinical symptoms. 
In the case of severe hypoglycemia, all effort must be used to maintain euglycemia as soon 
as possible. However, the appropriate therapeutic approach relies on correct diagnostic 
evaluation. In relation to the age of onset, different causes of hypoglycemia should be 
considered in neonates, infants, children and adults. 
The risk of hypoglycemia is declining during the life, low blood glucose level is the frequent 
problem, mainly in neonatal period. The majority of neonatal hypoglycemia are due to 
problems with the normal processes of metabolic adaptation after birth, and strategies 
enhance the physiologic transition should help prevent such episodes. Further investigation 
and specific intervention should be considered when hypoglycemia is unusual in severity, 
duration, or occurs in an otherwise low-risk infant (Desphande & Platt, 2005).  
Important factor for diagnosis is timing of hypoglycemia in relation to fasting. If hypoglycemia 
occured in a short period after meal (2-3 hours) and after overnight fasting, hyperinsulinism 
would be assumed. Low blood glucose level within  4-6 hours after ingestion is typical for 
defect in glycogenolysis. If hypoglycemia occurs more than 6 hours after feeding, disorders of 
fatty acid oxidation or defect in gluconeogenenesis are supposed (de Leon et al, 2008). In older 
patients, the fasting period inducing hypoglycemia is usually longer.   
Physical examination can also be helpful in diagnostic evaluation. The presence of central 
cleft lip (or palate), micropenis and undescended testes in male neonate strongly suggests 
the occurrence of hypoglycemia due to pituitary hormone deficiency. If TSH deficiency was 
associated, untreated infants would suffer from psychomotoric retardation, growth 
retardation is typical later at the age 2-3. Large for age newborns with recurrent 
hypoglycemia could be suspected of autosomal recessive form of hyperinsulinism, if mother 
did not suffer from diabetes in pregnancy. Short stature and hepatomegaly is a part of 
clinical picture of glycogen storage disease type 1 (Langdon et al, 2008).  
Hypoglycemia is expected in a risk group of neonates (e.g. premature, small for age) and in 
diabetic patients. If etiopathogenesis of low blood glucose level is unknown and 
unexpected, the sampling of  blood and urine at the time of hypoglycemia is crucial (critical 
sample). In diagnostic algorithm, it is necessary to measure plasma substrates: ketones 
(aminoacetate and hydroxybutyrate acids), lactate, free fatty acids, ammonia level, and  
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hormones: insulin, C-peptide, cortisol, growth hormone at the time of low blood glucose 
level. Hypothyroidism ought to be excluded in all patients with low blood glucose level. If 
hypoglycemia was less than 2,8 mmol/l (50 mg/dl), repeated sampling and measurement of 
counter-regulatory hormones, such as cortisol and growth hormone, would be suggested 30 
minutes after low blood glucose concentration. At the blood glucose level of 2,2 mmol/l and 
less, the peak values of cortisol and growth hormone are reached in half an hour, and are 
comparable to those in insulin stimulation test (Weintrob et al, 1998).   
At the time of hypoglycemia, the lack of ketones makes pediatric frequent diagnosis of 
ketotic hypoglycemia nonprobable. Ketoacidosis is also common in cortisol deficiency, 
whereas lactic acidosis is part of disorders of gluconeogenenesis like as glucose 6-
phosphatase deficiency. Ketones and lactate are the alternative fuel for brain, disorders with 
high plasma level of these substrates are linked with laboratory serious hypoglycemia 
without clinical symptoms of neuroglycopenia. Some patients may have only few symptoms 
at plasma glucose level as low as 1,1-1,7 mmol/l (20-30 mg/dl). On the other hand, in 
defects of ketogenesis, signs may begin to appear at plasma glucose level of 3,3 mmol/l (60 
mg/dl) during fasting. The average cut point of plasma glucose level to provoke clinical 
adrenergic and neuroglycopenic symptoms is 2,8 mmol/l (De Leon et al, 2008).  
High level of free fatty acids with hypoglycemia is a part of defects of fatty acid oxidation 
associated with coma, hepatocellular failure and hyperammonemia (Reye-like syndrome). 
Valproic acid can block β-oxidation, treatment of epilepsy may provoke Reye-like syndrome 
in some patients. Early supplementation with carnitine and riboflavin, avoidance of fasting 
and low-fat diet can be useful and  lifesaving. Acyl-carnitine profile of blood spots in 
newborn screening is able to detect most fatty acid oxidation disorders. Free fatty acids do 
not pass blood-brain barrier and can not be used as a energy substrate in brain. 
Hypoglycemic symptoms follow usually the same pattern for each patient. Especially in 
type 1 diabetes, it is important to teach patient and all family members how to recognize 
and treat hypoglycemia in a safe and effective manner as soon as possible. Coffee and cola 
caffeine may cause symptoms of hypoglycemia at a slightly higher blood glucose level than 
usually. The fact that caffeine enhances the intensity of symptoms warning hypoglycemia 
may be useful for patients with „hypoglycemia unawareness“. On the other hand, treatment 
of high blood pressure with β-blockers may have opposite effect and makes symptoms of 
hypoglycemia less obvious. Patients with diabetes on β-blockers treatment should check 
blood glucose level in case of sweating without any reason. It may be the only sign of a very 
low blood glucose. Similarly, few symptoms are noticed in diabetics treating for depression 
with SSRIs, patients may suffer from hypoglycemia unawareness, too (Hanas, 2004). 
The warning adrenergic symptoms precede typically neuroglycopenic ones and work 
as a brain protection. Diabetes mellitus may be associated with autonomic dysfunction, 
warning symptoms are being lost and hypoglycemia becomes unawareness. Frequent 
hypoglycemia may cause lowering of threshold for triggering adrenergic signs that start 
commonly at the blood glucose level 3,3-3,6 mmol/l (60-65 mg/dl) in diabetic patients. On 
the opposite side, if the average glycemia was 15 mmol/l  within a week, the warning 
symptoms could start at the blood glucose level 4,5-5,5 mmol/l (80-100 mg/dl).  
Neuroglycopenic signs are mostly independent on the recent blood glucose values, 
observed in glycemia below 2,8 mmol/l (Hanas, 2004) . 
For correct management of patients with hypoglycemia, two glucose thresholds must be 
distiguished. The first one is diagnostic glucose level, hypoglycemia is usually considered in 
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the case of plasma glucose value below 2,8 mmol/l. Such glucose concentration is helpful 
for immediate sampling of alternative fuels and hormones, and consequently for differential 
diagnosis of hypoglycemic patients. The second one is therapeutic glucose value, the goal of 
appropriate treatment of hypoglycemia is to maintain plasma glucose within normal range 
3,9-5,5 mmol/l (70-100 ng/ml) (Langdon et al, 2008).        
The glucose level can be measured as whole blood glucose or plasma glucose. Plasma glucose 
is approximately 11% higher than whole blood glucose. Methods of measuring glucose level 
with bedside glucose meters were originally designed for diabetes management. These 
monitors are adequate for management of hypoglycemia, but are not accurate enough for 
measurement of hypoglycemic level. Latest development in bedside monitoring has improved 
the technology, but is not sufficiently accurate and precise to establish a diagnosis of 
hypoglycaemia. As a screening test it may be useful, any meter blood glucose level less than 
3,3 mmol/l  should be confirmed by more precise laboratory measurement of whole blood or 
plasma glucose concentration (Gamma et al, 2000).  
Blood samples that are not processed promptly can have errorneously low glucose levels, as 
a result of glycolysis by red and white blood cells. At room temperature, the decline of 
whole-blood glucose can be 0,3-0,4 mmol/l/hr (5 to 7 mg/dl/hr). The use of inhibitors, such 
as fluoride, in collection tubes prevents this problem. Falsely low (or high) glucose values 
may occur with samples drawn from indwelling lines without adequate flushing of the 
saline (or glucose) infusate (de Leon et al, 2008).  
2. Management of hypoglycemia in neonates and infants 
Traditionally, lower standards for hypoglycemia were accepted in neonates. The major 
reason was statistical, low blood glucose is so common in neonatal period that it must be 
taken as a normal. Recently, the same definition and the same targets for treatment of 
hypoglycemia have been recommended in neonates and in older patients (de Leon et al, 
2008). Moreover, the consequences of delayed diagnosis or inadequate management may be 
more harmful to a developing brain in neonates and infants (Menni et al, 2001).  
Previously, the blood glucose concentration at which clinical signs occured were used to 
define hypoglycemia. These signs, such as changes in level of alertness and tone, apnoe, 
tremors or seizures are not specific in neonates and infants. In the first few hours, after birth 
fuels apart from glucose are also relevant in providing brain energy. Therefore the presence 
or absence of clinical signs can not be used to differ between normal and abnormal glucose 
levels, although decreased level of consciousness or seizures should always suggest the 
possiblity of hypoglycemia (Desphande & Platt, 2005). 
The cerebral fuel economy depends on blood glucose level, the avaliability of alternative 
fuels such as ketones and lactate, the local adaptation of microcirculation, the interaction 
with other brain cells and the concurent neonatal condition such as hypoxia and sepsis 
(Salhab et al, 2004). The immediate consequence of transition from fetal to neonatal life is the 
interruption of continuous glucose supplies. After birth, there is a rapid fall in blood glucose 
level, reaching a nadir between 1-2 hr in healthy term infants as well. Such low blood 
glucose level is usually accompanied by ketogenic response, particulary in breast-fed 
infants. Ketones provides alternative fuel for brain and prevents the neonate to become 
symptomatic. Even in the absence of any nutritional intake, the blood glucose rises 
significantly within 3 hrs due to counter-regulatory hormone response. Therefore, healthy 
asymptomatic neonates are proposed to avoid the blood glucose measurement during the 
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first 2-3 hrs after birth and only glycemia less than 2,0 mmol/l requires other intervention 
(Desphande & Platt, 2005). However, up to 10% of normal term neonates are not able to 
maintain plasma glucose concentrations above 1,7 mmol/l (30 mg/dl), if their first feeding 
is delayed for 6 hrs after birth (Lindley & Dunne, 2005). In case of this late first feeding, 
glycemia above 2,8 mmol/l (50 mg/dl) has been observed only in two thirds of  healthy 
neonates. Promotion of first feeding soon after delivery is the basic approach to prevention 
of such blood glucose declining. 
Some common maternal or neonatal problems expose a baby at risk of significant 
hypoglycemia (Table 1). Often measurements of blood glucose are helpful, even though in 
asymptomatic risk neonates. Severely intrauterine growth retarded (IUGR) neonates may 
have low cord blood glucose concentrations due to intrauterine hypoglycemia. On the other 
hand, hypoglycemia should be excluded in all clinically unwell infants. Clinical signs of 
common neonatal illnesses are shared by those with hypoglycemia. Moreower, many 
neonatal disorders can lead to hypoglycemia (Desphande & Platt, 2005). 
Blood glucose concentrations show a cyclic response to an enteral feeding, reaching a peak 
approximately one hour after meal and a nadir just before the next feeding. In risk neonates, 
initial blood glucose measurement, immediately before the second feeding, may detect the 
most babies who can not manage adequately glucose homeostasis. Once or twice a day pre–
feeding blood glucose determination may be sufficient in stable neonates, since the clinical 
condition has not been changed or the previous volume of milk has not been restricted. 
Laboratory standard blood glucose measurement is reliable and preferable to inaccurate 
reagent strip-based estimations (de Rooy & Hawdon, 2002). 
  
Maternal 
conditions 
• Diabetes (pregestational and gestational) 
• Drug treatment (β – blockers, oral hypoglycemic agents) 
• Intrapartum glucose administration 
Neonatal 
problems 
• Preterm 
• Intrauterine growth restriction 
• Perinatal hypoxia – ischemia 
• Hypothermia 
• Infection 
• Polycythemia 
• Infants on parenteral nutrition 
• Obvious syndromes (e.g. midline defects, Beckwith – 
Wiedemann syndrome) 
Table 1. „At – risk“ infants who require monitoring of blood glucose concentrations 
(Deshpande  &  Platt, 2005).  
The most common neonatal hypoglycemia is due to delay of normal metabolic adaptation 
after birth. Occasionally, especially in IUGR neonates, a period of a week or more with high 
intravenous glucose infusion rate may be required. Blood glucose concentration often falls 
down in perinatal asphyxia, polycythemia, sepsis and with maternal use of β-blockers. 
Rarely, hypoglycemia is the presenting symptom of hormonal disorders or inborn errors of 
metabolism, such as hyperinsulinism (Yap et al, 2004), hypopituitarism and fatty acid 
oxidation disorder. Some clues can make hormonal or metabolic disorder very suspected: 
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• Family history of sudden infant death, Reye-like syndrome, or developmental 
delay 
• Healthy, appropriate for gestational age, term infant with symptomatic 
hypoglycemia 
• Hypoglycemia with midline defects, micropenis, exomphalos 
• Hypoglycemia with seizures or abnormalities of conciousness 
• Persistent or recurrent hypoglycemia 
• Glucose infusion rate more than 10 mg/kg/min 
 
Sample Investigations 
Blood 
• Intermediary metabolites (glucose, lactate, 
pyruvate, alanine, free fatty acid, glycerol and 
ketone bodies) 
• Serum electrolytes, liver functions and acid – base 
status, C reactive protein 
• Ammonia 
• Amino acids 
• Total and free carnitine 
• Acylcarnitine profile 
• Insulin,  C - peptide, growth hormone, IGF1, 
IGFBP3, cortisol and thyroid hormones 
• Galactosemia screen  
Urine  
• Ketones by dipstick 
• Organic acids and aminoacids 
• Reducing substances (galactose and fructose) 
Others 
• Ophthalmic examination 
• Cranial ultrasound scan and/ or MRI 
Table 2. Suggested investigations in hypoglycemic patient with suspected metabolic/ 
endocrine disorder (Deshpande  & Platt, 2005). 
If neonate meets criteria for metabolic-hormonal disturbances, crucial point will be to obtain 
appropriate samples for examination of intermediary metabolites and hormones at the time 
of hypoglycemia. The second sample in a half an hour after episode may be useful to 
evaluate counter-regulatory response, mainly in newborns suspected of pituitary deficiency. 
If such samples are not obtained, the correct diagnosis may be delayed, furthermore, 
invasive testing and controlled fasting may be required. It can be helpful to prepare a 
hypoglycemia kit with suitable containers and instructions for instance of sudden 
hypoglycemic episode (Table 2). Further management should involve consultation with a 
specialist in pediatric endocrinology and metabolic medicine (Desphande & Platt, 2005). 
2.1 Hormone deficiency 
Some newborns with hypoglycemia are supposed to have pituitary deficiency, those 
suffering from midline defects (cleft lip or palate) and micropenis with undescended testes. 
At first, the basal sample of free thyroxine, TSH, cortisol, IGF-1, IGF BP-3, sex hormones 
should be recommended. Typically, lower concentrations of thyroxine, cortisol and IGF BP-3 
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are measured in infants with pituitary deficiency. Decreased IGF BP-3 level has greater 
value to diagnosis of growth hormone deficiency in infancy. Despite importance of 
evaluation IGF-1 levels in children, these are rarely helpful in neonates. In fact, serum IGF 
BP-3 should be performed as the test of choice in suspected neonatal growth hormone 
(GH) deficiency. The use of standard GH stimulation tests is not recommended in 
newborns, except for safe glucagon test 0,03–0,1 mg/kg. Cortisol and GH levels are 
measured in a basal sample, and furthermore in 5 consequent samples (0, 60, 90, 120, 150, 
180 min). Cortisol and GH sampling half hour after clinically significant and laboratory 
proved low blood glucose level (≤ 2,2 mmol/l) can confirm GH deficiency, and protect 
child from prolonged redundant testing (Weintrob et al, 1998). Several mutation in genes 
involved in pituitary development (POUF1, PROP1, TPIT) has been reported in infants 
with hypoglycemia due to pituitary deficiency. Congenital hypopituitarism may not be 
diagnosed until a baby is several months old. Abnormal growth is usually noticed only 
after 1-2 years of life and recurrent hypoglycemia in infants with confirmed GH deficiency 
is an indication to start GH treatment, especially in those on thyroxine and hydrocortisone 
therapy (Randell et al, 2007).  
Neonates with ambigous genitalia are always suspected of congenital adrenal 
hyperplasia, although presenting clinical signs of mineral disturbances rather than 
hypoglycamia may be apparent from 2 to 4 weeks of life. Treatment with hydrocortisone 
and fludrocortisone should be started immediatelly in such infants, after appropriate 
hormonal sampling. Chromosome analysis, hormone measurements (especially 17-
hydroxyprogesteron, androstendion, cortisol and testosterone) are necessary in diagnostic 
approach, the most common cause is 21-hydroxylase deficiency. If enzyme defect is 
comfirmed by hormonal measurements, identification of mutation in genes (CYP 21, CYP 
11β, and other) should folow in management. Wolman disease and congenital adrenal 
hypoplasia, two other rare causes of adrenal failure have been described in neonates and 
infants (Randell et al, 2007).  
2.2 Metabolic inborn error  
Hypoglycemia induced by first feeding, especially in combination with vomiting, diarrhoea 
and jaundice, should be suspected from galactosemia (galactose-1-phosphate uridyl 
transferase deficiency or UDP galactose-4-epimerase deficiency). Exposure to milk results in 
acute deterioration of multiple organ systems, including liver dysfunction, poor feeding, 
weight loss, renal tubular dysfunction, neutropenia, coagulopathy and Escherichia coli 
sepsis. Galactosemia should also be excluded in all neonates with these findings and 
concomitant E.coli sepsis. Some screening programs in newborns have included 
galactosemia routinely. A galactose restricted diet will reverse effectively multiorgan 
dysfunction, and will eliminate the risk of hypoglycemia during childhood. However, long-
term effect on mental functions, speech and ovarian function may persist despite 
appropriate dietary therapy in individuals with galactosemia (Leslie, 2003). 
Nonspecific symptoms occuring 3-6 months after birth, such as failure to thrive and 
vomiting, may be a part of clinical picture of hereditary fructose intolerance due to fructose 
1-phosphate aldolase deficiency. Exclusively breast-fed and formula-fed infants are healthy 
unless fruits and juices are added into diet. The worsening of symptoms and hypoglycemia 
with feeding should rise clinical suspicion. Low chronic exposure to fructose causes failure 
to thrive and chronic liver disease. Biochemical findings of elevated fructose level may be 
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confirmed by enzyme assay of liver or small intestinal biopsy. Treatment consists of strict 
dietary avoidance of fructose, sucrose and sorbitol (Wong, 2005). 
Disorders of gluconeogenesis should be considered in infants with fasting hypoglycemia 
during intercurrent illness, especially in the case of positive family history to unexplained 
sibling death. Pattern of characteristically abnormal organic acids in urine is usually present 
in infants with disruption of gluconeogenesis. Fructose 1,6-diphosphatase is a key 
regulatory enzyme of gluconeogenesis from all substrates (fructose, glycerol, lactate and 
amino acids). Deficiency of such enzyme leads to hepatomegaly, hypoglycemic seizures and 
hyperventilation due to lactic acidosis and ketoacidosis. Developmental delay and mental 
retardation may be the consequence of untreated infants. Unlike hereditary fructose 
intolerance, liver and renal tubular dysfunction are atypical. Infants with fasting 
hypoglycemia and lactic acidosis should be suspected of defects of gluconeogenesis, 
diagnosis is confirmed by enzyme assay in liver biopsy. Chronic treatment consists of 
avoidance of fasting and reduction of fructose in diet, correction of metabolic acidosis is 
necessary (Langdon et al, 2008). Continuous nasogastric infusion may be helpful overnigt 
and during intercurrent illness. Rarely, pyruvate carboxylase deficiency has been found. In 
addition to hypoglycemia, hyperalaninemia and lactic acidosis, elevated pyruvate is 
comfirmed. Some infants develop hyperammonemia, hypercitrulinemia, hyperlysinemia 
and hyperprolinemia. Diagnosis may be proven by measurement of enzyme activity in 
fibroblasts. In addition to metabolic acidosis correction, substitution of Krebs cycle 
substrates has been suggested, as well as supplementation with coenzymes of pyruvate 
dehydrogenase complex - thiamine and lipoic acid (Ahmad et al, 1999). Except such genetic 
enzymatic defects, alcohol ingestion and salicylate treatment may cause iatrogenic block of 
gluconeogenesis.       
Medium-chain acyl-coenzyme A dehydrogenase deficiency (MCAD) is the most frequent 
disorder of fatty acid oxidation. Neonatal screening in Pensylvania has shown an incidence 
1:9 000 live birth (Ziadeh et al, 1995). Although there is a significant heterogeneity in 
presentation of MCAD, the most common sign is intermittent hypoketotic hypoglycemia 
during intercurrent infection with decreased oral intake. Family history of sibling death rises 
suspicion. Severe form presents as a Reye-like syndrome with hyperammonemia, 
hepatocellular failure and coma. Affected patients could also be misdiagnosed with sudden 
infant death syndrome (Roe & Ding, 2001). Evaluation of suspected errors in fatty acid 
oxidation should first include the determination of plasma acylcarnitine profile by mass 
spectrometry and measurement of plasma total, esterified and free carnitine. Determination of 
urinary organic acids with assessment of dicarboxylic aciduria is also very useful. Patients, 
whose disorder cannot be confirmed by these tests, may require further evaluations, including 
assays of fatty acids oxidation and specific enzyme assays in cultured skin fibroblasts or 
lymphoblasts. Direct DNA mutational analysis can be performed, particularly in MCAD. 
Therapeutic approach consists of avoidance of fasting and high fat intake, although normal 
amounts of fats do not seem to be harmful. The use of cornstarch (1-2g/kg every 4 hours) and 
carnitine supplementation has been advocated (Rinaldo et al, 2002).   
2.3 Neonates at risk of hypoglycemia     
Prevention of low blood glucose concentrations is the goal of management in newborns at 
risk of hypoglycemia. In healthy appropriately grown term infants, facilitating normal 
feeding is all that is needed. Breast-fed neonates demonstrate lower blood glucose and 
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higher ketone concentrations than formula-fed ones. This starvating, ketogenic response is 
typical for physiologic transition from fetal to neonatal metabolism, as in other mammals 
(de Rooy & Hawdon, 2002). For infants, who are able to tolerate enteral feeding, increasing 
amount of milk should be the first strategy. Although oral dextrose solution may be 
recommended, the milk contains approximately twice more energy as equivalent volume of 
10% dextrose.  
Severely IUGR neonates may be hypoglycemic in utero, delayed metabolic adaptation will 
be expected in those infants soon after birth. Cord blood glucose level determination may be 
helpful, the concentration less than 2,0 mmol/l can reveal IUGR infants at high risk of 
symptomatic hypoglycemia. In order to precede clinical consequences, appropriate 
intervention seems to be prophylactic intravenous glucose infusion as soon as possible 
(Desphande & Platt, 2005). In  IUGR infants, early enteral feeding is recommended and 
breast-feeding is the approach of choice. If child remains hypoglycemic despite an adequate 
milk intake, intravenous glucose infusion at a rate equal to the hepatic glucose production 6-
8 mg/kg/min (85-120 ml of 10% glucose/kg/24 hrs) is necessary. Due to functional 
hyperinsulinism in some IUGR infants, glucose intake may be increased (10 mg/kg/min or 
more) occasionally.  
Preterm infants with respiratory distress (usually less than 32 weeks of gestation) require 
always intravenous glucose infusion, at least 6 mg glucose/kg/min. Near term infants are 
often able to suckle the breast or bottle but skillful support of nurse may be needed. 
Supplementation of milk with glucose polymers and energy supplements may increase the 
risk of necrotizing enterocolitis due to bowel osmolality (Desphande & Platt, 2005). 
In infant of diabetic mother, the highest incidence of hypoglycemia occurs between 4-6 hr after 
birth, interval of onset may extend up to 48 hrs. Tighter metabolic control during pregnancy 
and delivery is associated with decreased frequency of neonatal hypoglycemia. In particular, 
maternal blood glucose more than 8 mmol/l during parturition is linked with higher risk of  
hypoglycemia in neonate. Insufficient metabolic compensation of pregnant diabetic woman is 
the reason of neonatal macrosomia due to prolonged fetal hyperinsulinism (Taylor et al, 2002). 
Management approach to neonate of diabetic mother consists of early enteral feeding and 
regular pre-fed glucose monitoring, unless the later blood glucose level is normal one. 
Excessive glucose infusion rate in baby is responsible only for another pancreatic stimulation 
and should be avoided. Similarly, administration of glucagon immediately after birth is not 
routinely recommended, otherwise rapid hepatic glucose release can further stimulate insulin 
secretion and augment the tendency to hypoglycemia. 
The use of intravenous glucose bolus is inevitable in symptomatic infants with glycemia 
below the normal range. Recommended bolus therapy is 2 ml/kg of 10% glucose solution 
(200 mg glucose/kg). The dose has been efficacious in rapid release of clinical symptoms 
like as depressed alertness, hypotonia, apnoe or seizures, otherwise it usually restores 
normal blood glucose level without later hyperglycemia. Intravenous administration of 
bolus should be followed by an increase in the rate of glucose infusion. Treatment of 
neonatal hypoglycemia with intermittent boluses alone is not logical, the need for such 
boluses is an indication for rising continuous glucose infusion rate. Boluses of hypertonic 
(20% or 40%) glucose solutions should be avoided. In a similar way, gradual rather than 
large reduction in the rate of intravenous glucose infusion is helpful to maintain stable 
blood glucose concentration.     
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Glucagon promotes early neonatal glycogenolysis from liver and also stimulates 
gluconeogenesis and ketogenesis. Intravenous bolus dose of 200 µg/kg was used in 
previous studies, such administration may provoke further hypoglycemia due to 
hyperglycemia induced insulin secretion. Therefore, application of glucagon bolus should 
be followed by continuous glucose infusion. In a study of 55 neonates with hypoglycemia of 
various etiologies, continous infusion of glucagon (0,5-1,0 mg/day) increased blood glucose 
concentration significantly within 4 hrs after starting of infusion. The frequency of 
subsequent hypoglycemia has been decreased with continuous glucagon therapy (Mirales et 
al, 2002). The occurrence of severe hyponatremia has been reported in a preterm infant, but 
the relationship with glucagon infusion seems to be unlikely (Charsa et al, 2003, Coulthard 
& Hey, 2002). 
3. Management of neonatal hyperinsulinism 
Most infants with hyperinsulinism present within neonatal period, although infantile and 
childhood forms are also described. In general, excessive glucose requirement with infusion 
rate more than 10 mg/kg/min is suspected of hyperinsulinism. Traditionally, the diagnosis 
of hyperinsulinism is based on demonstrating inappropriately high insulin concentration at 
the time of hypoketotic hypoglycemia (Table 3). Diagnosis is confirmed by insulin level 
more than 2,0 mIU/l and glycemia below 2,8 mmol/l at the same time. Intravenous 
adminstration of glucagon is followed by glycemic response bigger than 1,7 mmol/l within 
15- 30 minutes in infants with hyperinsulinism (de Leon et al, 2008).   
 
Criteria for diagnosing hyperinsulinism based on critical sample 
Critical sample must be drawn at time of hypoglycemia (plasma glucose < 50mg/dl) 
• Detecable insulin (>2 mIU/l) 
• Low free fatty acids (< 1,5 mmol/l) 
• Low ketones (plasma β hydroxybutyrate < 2,0 mmol/l) 
Inappropriate glycemic response to 1mg intravenous glucogen at time of hypoglycemia 
(glucose rise > 30mg/dl in 20 minutes) 
Table 3. Criteria for diagnosing hyperinsulinism based on critical sample (Langdon et al, 
2008). 
The majority of neonatal hyperinsulinism is transient, these form has been observed in 
neonates with maternal diabetes, Beckwith – Wiedemann syndrome, Sotos syndrome, 
Perlman syndrome, birth asphyxia, polycythemia, rhesus incompatibility and severe 
intrauterine growth retardation (Baujat et al, 2004). Such perinatal stress-induced 
hyperinsulinism may persist for several days to several weeks, but not longer than 6 
months (Hoe et al, 2006). Infants with prolonged stress hyperinsulinism are usually good 
responders to diazoxide therapy. Glucocorticoids are not effective in controlling of 
hyperinsulinism.  
Hyperinsulinism is the most common cause of persistent or recurrent hypoglycemia in 
infancy. Generally, the persistent hyperinsulinism is relatively rare (1:30 000- 1:50 000) but 
may lead to neurological damage and lifelong handicap. Up to 20% of infants suffering from 
congenital hyperinsulinism exhibits neurological defect (Menni et al, 2001). Approximately 
60% of patients with persistent hyperinsulinism present within the first week of life, the 
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most severe forms start earliest. However, all of the genetic causes of hyperinsuslinism may 
be initially diagnosed in older infants and children (Langdon et al, 2008). 
Infants with congenital hyperinsulinism are usually born in term and macrosomic, similar as 
neonates of diabetic mothers. On the other hand, low birth weight or preterm birth does not 
exclude persistent hyperinsulinism (Aynsley-Green, 2000, Yap et al, 2004). Most infants are 
apparently macrosomic and plethoric and may have characteristic facial features with high 
forehead, large and bulbous nose, smooth philtrum and thin upper lip. Later in infancy, the 
only clinical sign may be unexplained developmental delay (de Lonlay et al, 2002 a). 
Exomphalos in neonates with macrosomia and macroglossia enables to diagnose Beckwith-
Wiedemann syndrome (BWS 1:10 000). Hyperinsulinemic hypoglycemia occurs 
approximately in 50% infants, and is usually mild and transient. Higher predisposition to 
childhood tumors has been described in BWS patients, analysis of chromosome 11p15 
finding aberrant H19 and KCNQ1OT1 hypomethytalion may identify patients at increased 
risk of cancerogenesis (Bliek et al, 2001). Sotos syndrome (cerebral gigantism) involves also 
combination of somatic overgrowth and hyperinsulinism, the major cause is 
haploinsufficiency of NSD1 gene (Baujat et al, 2004).   
The appropriate management of hyperinsulinemic infants is based on maintaining of blood 
glucose above 3,5 mmol/l. Even though of sufficient enteral feeding, the supplemental 10-15% 
glucose intravenous infusion is often needed, otherwise glucose requirement is usually 15-20 
mg/kg/min. A secure central intravenous access should be obtained immediately after 
diagnostic evaluation. If intravenous cannula is resited, intramuscular glucagon 
administration 100 µg/kg is recommended. Hyperinsulinemic infants require intensive 
medical care monitoring at a centre specialized in management of hyperinsulinism. Once the 
infant is stabilized, a planned transport should take place. Delayed refferal to the centre may 
be the reason of  neurologic consequences associated with disorder (Desphande & Platt, 2005).   
The majority of transient forms of congenital hyperinsulinism will settle during the first 
month of life. This period can be spent evaluating of responsiveness to drugs therapies and 
attempting to introduce normal enteral feeding. After 4 weeks, as soon as diagnosis of 
congenital hyperinsulinism is confirmed, rapid genetic analysis of the affected child and 
parents using HPLC screening followed by sequencing of target genes should be 
recommended (Lindley & Dunne, 2005). 
The most common and severe cause of persistent hyperinsulinism is due to loss of function 
mutation of the pancreatic β-cell K+ATP channel consisting of 2 subunits. K+ATP  
hyperinsulinism may be diffuse or focal. More than 100 mutations of ABCC8 (encoding SUR1 
subunit) and 20 mutations of KCNJ11 (encoding Kir6.2 subunit) have been found so far. 
Neonates with recessive form present as a large for gestational age with very severe 
hypoglycemia immediately after birth, characteristic sign is usually poor responsiveness to 
diazoxide. Dominant form of K+ATP hyperinsulinism may occur in family members, the onset 
of milder hypoglycemic symptoms is often later in infancy and childhood. These patients 
reflect better responsiveness to diazoxide (Grimberg et al, 2001). In addition, defects in SUR1 
subunit may be inherited in three different mechanism, loss of heterozygosity has been 
identified, except for recessive and dominant patterns. The association of recessive mutations 
with diffuse hyperinsulinism, as well as loss of heterozygosity with focal form, has been found 
in infants with SUR1 defects (Langdon et al, 2008).  
The second most common form in infants is hyperinsulinism/hyperammonemia (HI/HA) 
syndrome caused by gain of function mutation of GLUD1 (encoding glutamate 
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dehydrogenase GDH). Most cases are sporadic due to de novo mutations. Approximately 
20% of these disorders are familial with autosomal dominant inheritance. Typically, 
neonates suffering from HI/HA syndrome are appropriate for gestational age. Episodes of 
symptomatic hypoglycemia may not been recognized until 1-2 years of age. Patients with 
HI/HA syndrome have relatively mild fasting hypoglycemia. However, after ingestion of 
protein meal, severe protein-sensitive hypoglycemia can happen within 30-90 minutes. 
Diazoxide therapy is usually effective to control fasting and protein-induced hypoglycemia. 
Differential laboratory finding is slightly elevated ammonia level (60-150 µmol/l) without 
therapy requirement. The lack of clinical hyperammonemic symptoms may be explained by 
increased GDH enzyme activity in brain of affected individuals (Li et al, 2006). Less frequent 
form of congenital hyperinsulinism presenting with fasting hypoglycemia is due to 
activating mutations of GCK (glucokinase), sometimes showing autosomal dominant 
pattern. The age of onset and severity of symptoms varies markedly (Cuesta-Munoz et al, 
2004). Rarely, mutation of  HADHSC gene (encoding short chain L-3-hydroxyacyl-CoA 
dehydrogenase SCHAD) with autosomal recessive inheritance may be identified as a cause 
of hyperinsulinism in infants (Hussain et al, 2006).           
Occasionally, congenital carbohydrate-deficient glycoprotein syndrome, also known as 
congenital disorders of glycosylation (CDG), has been identified as a cause of neonatal 
hyperinsulinism. Unlike other forms of hyperinsulinism, CDG often leads to involvment of 
other systems, especially the brain, liver, gut and skeleton. The diagnosis is usually confirmed 
by identification of hyposialylated serum transferrin by isoelectric focusing (Fang et al, 2004).  
Less than 20% of neonates with persistent congenital hyperinsulinism will respond to 
diazoxide therapy, a K+ATP channel opener (De Lonlay et al, 2002 b). Diazoxide binds to 
the SUR1 subunit of the K+ATP channel. Infants with no functional K+ATP channels at the 
β-cell membrane are not expected to respond to diazoxide therapy. On the other hand, 
patients suffering from hyperinsulinism-hyperammonemia syndrome with normal K+ATP 
channel are more likely better responders than those with ABCC8 loss of function mutation. 
So genetic analysis of congenital hyperinsulinism is useful in predicting of drug 
responsiveness. The daily requirement of diazoxide varies between 5-25 mg/kg divided in 
several doses. Otherwise, diazoxide as a channel opener retains sodium and water, 
chlorothiazide has been successfully added to counteract this side event. Appart from acting 
as a diuretic, chlorothiazide has also direct β-cell pottasium channel opening activity. In a 
purpose to supply sufficient glucose, large volumes of intravenous fluids are infused to 
hyperinsulinemic infants and enhance the danger of severe water retention (Silvani et al, 
2004). 
Somatostatin analogues are able to inhibit insulin secretion in various manners by inducing 
hyperpolarisation of β-cells, direct inhibition of the voltage-gated calcium channel and more 
distal insulin secretory pathways. Recommended dose of somatostatin analogues is 5-20 
mg/kg/24 hrs intravenously or subcutaneously, usually in combination with diazoxide. If 
diazoxide is contraindicated and intravenous glucose requirement is too high, somatostatin 
therapy may be used as a first line treatment. Safety and efficacy of long term treatment in 
infants and children has been discussed (Dunne et al, 2004).   
The intravenous administration of glucagon (1-10 µg/kg/hr) may be helpful in acute 
management of infants with hyperinsulinism, rising glycemia reflects the changes in 
gluconeogenesis and glycogenolysis. For long-term therapy, glucagon works like as insulin 
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secretagogue and is recommended usually in combination with other treatment lowering 
insulin secretion (Aynsley-Green, 2000). Considerable distinction has been reported on 
glycemic effect of Ca 2+ channel blockers. According to reports of  few centres, some 
hyperinsulinemic infants may profit from nifedipine chronic therapy (Lindley et al, 1996). 
 
Seletctive drugs for hypoglycemic disorders 
1. Intravenous glucose rescue doses 
• Dextrose emergency bolus: IV push 0,2g/kg bolus (2ml/kg of dextrose 10%), 
followed by D 10% continuous infusion of 5ml/kg/hr 
• If plasma glucose not corrected after 15 minutes, bolus 2ml/kg of 10% dextrose 
and increase continuous infusion by 25% to 50% 
2. Glucagon (emergency treatment only in case of insulin-induced hypoglycemia) 
• 1 mg intramusculary or intravenously (0,03-0,1 mg/kg) 
• Side effects: vomiting and rebound hypoglycemia 
3. Diazoxide (use in hyperinsulinism or sulfonylurea overdose) 
• 5 – 15mg/kg/day divided into two or tree doses (if given by IV route, must be 
given over 15 minutes to avoid hypotension) 
• Start with maximum dose (15mg/kg to test), then lower as possible (responders 
usually require 10mg/kg or less) 
• Side effect: fluid and sodium retention, hypertrichosis 
4. Octreotide 
• Start at 2 to 5 mg/kg/day and increase to 20 mg/kg/day SC divided into 3 or 4 
doses 
• Side effect: transient diarrhoea, abdominal discomfort, gallstones, transient 
growth impairment 
5. Cornstarch (for glycogen storage disease) 
• 1 – 2g/kg/dose (freshly prepare each dose by suspending in cold sugar – 
containing liquid) 
• Effect last 4 to 6 hrs 
• Not well absorbed in infancy 
• Side effect: diarrhoea 
6. Carnitine (for free fatty oxidation disorder) 
• 100mg/kg/day divided into three or four doses 
• Side effects: diarrhoea and fishy body odour 
Table 4. Therapy of hypoglycemia (IV intravenous and SC subcutaneous) (Langdon et al, 2008) 
Neonates with severe forms of cogenital hyperinsulinism can usually be stabilised using the 
measures mentioned above (Table 4). After clinical improvement and stable glucose infusion 
rate, the oral feeding can start substantially. The response to enteral feedings, as well as 
protein load, may result in further stimulation of insulin secretion and recurrent 
hypoglycemia. In such infants, the appropriate management seems to be parenteral 
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nutrition, although this approach may also augment insulin release from β-cells (Magge et 
al, 2004). 
Clinically, infants with focal lesions are indistinguishable from those with diffuse 
hyperinsulinism. The focal lesions are potentially curable by surgery, whereas the outcome 
of diffuse K+ATP hyperinsulinism is worse. Furthermore, near total pancreatectomy (95-
98% of pancreas), invasive treatment of severe diffuse hyperinsulinism, is associated with 
a high risk of later development of diabetes mellitus. Focal lesions (usually less than 10 mm 
in diameter) are frequently not visible at laparotomy, the determination of appropriate 
diagnostic methods is necessary to differentiate focal hyperinsulinism from diffuse one. 
Significant different surgerical approach depends on reliable and accurate diagnostic 
evaluation. Conventional imaging methods including ultrasound, ocreotid scintigraphy, 
and magnetic resonance imaging are usually meaningless (Lindley & Dune, 2005).  
Interventional radiology methods, such as transhepatic portal venous insulin sampling and 
selective pancreatic arterial calcium stimulation have only modest success and are 
technically difficult and highly invasive, predominantly in small infants. During sampling 
procedure, the blood glucose concentrations should be kept below 3,0 mmol/l to 
demonstrate insulin hypersecretion in all or in isolated samples. Such glycemia without 
ketones may provoke clinical signs, especially in hyperinsulinism. Recently, positron 
emission tomography (PET) scans with fluorine-18, L-3, 4-dihydroxyphenylalanine (18F-
fluoro-L-DOPA) have been found to accurately discriminate focal form from diffuse 
hyperinsulinism. In infants  with focal hyperinsulinism, there is a local accumulation of 18F-
fluoro-L-DOPA. Combined PET and computed tomography (CT) images make lesion 
possible to be localized (Ericson et al, 1997). 
4. Management of hypoglycemia in children and adults 
Comparing to adults, children have very limited glucose homeostasis because of smaller 
reserves of liver glycogen and muscle protein. Moreover, glucose consumption is relatively 
high due to larger brain-to-body-mass ratio in children. For example, the fuel stores of a 10 
kg infant are only 15% of those of an adult. The real consequence of mentioned differences is 
varios approach to fasting in children and adults. Exposing infants to fasting is not without 
risk, particularly if fatty acid oxidation disorders or adrenal insufficiency are present (de 
Leone et al, 2008).  
Infants younger than 1 year should not be fasted more than 24 hrs, while in older children 
the maximum fasting is 36 hrs. Adults usually require to decrease plasma glucose level 
below diagnostic threshold more than 48 hrs (maximally 72 hrs). The fasting test is 
interrupted, when the plasma glucose falls below  2,8 mmol/l. This starving may be ended 
sooner, if plasma β-hydroxybutyrate rises above 2,0 mmol/l or in the case of any clinical 
signs suggesting hypoglycemia. At the time of hypoglycemia, critical sampling of 
alternative fuels (ketones, lactate and free fatty acids), insulin and counter-regulatory 
hormones (mainly cortisol and growth hormone) is crucial (Table 5). The result of fasting 
test may be affected by β-blockers treatment and unrecognized hypothyroidism, these two 
possibilities should be excluded before fasting. Especially in suspicion of hyperinsulinism, 
the fasting test may be ended with intravenous glucagon admininstration to evaluate the 
glycemic response (de Leon et al, 2008). 
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 Fasting 
Hypoglycemia 
Acidosis No Acidosis 
Fuel 
Response 
Lactic acidosis Ketoacidosis 
Free fatty acids >
1,5 mmol/l 
Free fatty acids <  
1,5 mmol/l 
Possible 
Disorders 
G – 6 – 
Phosphatase 
deficiency 
Fructose 1,6 – 
diphosphatase 
deficiency 
Pyruvate 
carboxylase 
deficiency  
Normal neonates 
Normal Ketotic 
hypoglycemic 
Glycogen storage 
disorder 
Growth hormone 
deficiency 
Cortisol 
deficiency 
Fatty acid 
oxidation 
disorders  
Normal neonates 
Hyperinsulinism 
Panhypopituitarism 
Small for 
gastational age, 
birth asphyxia 
 
Further Test Gluconeogenic 
precursors 
Glucagon 
stimulation test 
Tests of pituitary 
& adrenal 
function  
Glucagon 
stimulation test  
Acyl – carnitine 
profile 
Glucagon 
stimulation test  
Tests of pituitary, 
adrenal, thyroid 
function 
Insulin assay 
Other tests for 
hyperinsulinism 
Table 5. An algorithmic approach to hypoglycemia (de Leon et al, 2008). 
4.1 Ketotic hypoglycemia 
Ketotic hypoglycemia is the most common cause of low blood glucose level in chilhood. 
Usually, ketotic hypoglycemia begins as recurrent morning episodes of fasting hypoglycemia 
at the age of 2 or 3. The most of cases disappear spontaneously at the age of 8 to 9. Typically, 
partial or complete vomiting of evening meal is reported by parents in history. Especially, 
hypoglycemic episodes are likely to occur during periods of intercurrent illness with limited 
food intake. At the time of documented hypoglycemia, high level of ketones are measured in 
blood and urine, the plasma insulin concentration is typically low (< 2 mIU/l). Plasma alanine 
values are markedly reduced in children with ketotic hypoglycemia after ovenight fasting. 
Infusions of alanine produce a rapid rise in plasma glucose concentration without significant 
changes in lactate or pyruvate levels. This suggests that a deficiency of substrate, rather than 
defect in gluconeogenesis, plays a role in etiopathogenesis. Alanine, as a major 
gluconeogenetic amino acid precursor, is released from muscle during periods of caloric 
reduction. Children suffering from ketotic hypoglycemia are usually smaller than those of 
same age, reduced muscle mass in such patients may partially explain decreased supplies of 
gluconeogenic substrates (Stanley, 2006). 
The diagnosis of ketotic hypoglycemia can be claimed only after exclusion of the others. 
Recurrent hypoglycemia with ketosis may occur in the case of hormone deficiencies, defects 
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in gluconeogenesis and glycogen metabolism. Sometimes, the diagnosis demands the 
confirmation gained by supervised fasting. Low blood glucose level in combination with 
elevated ketones and free fatty acids develops within 14 to 24 hrs in most children with 
ketotic hypoglycemia. Prevention of ketotic hypoglycemia involves frequent high-
carbohydrate feedings, as well as overnight fasting should be shortened. The child with 
ketotic hypoglycemia should not fast more than 12 hrs. During intercurrent illness, parents 
ought to test the urine of child, the presence of ketones precedes hypoglycemia by several 
hours, and such ketones in urine may be the indicator of subsequent low blood glucose. In 
the presence of ketonuria, high-carbohydrate liquids should be offered to child. Vomiting 
child with ketotic hypoglycemia should be reffered to the hospital for intravenous glucose 
administration (Langdon et al, 2008).   
4.2 Hyperinsulinism 
All genetic causes of hyperinsulinism may be diagnosed later in childhood, these are usually 
not so severe as persistent neonatal forms. In adolescence and adulthood, insulinoma 
appears more frequent cause of hyperinsulinism comparing to genetic ones. Insulin-
secreting adenomas (insulinoma) of pancreas are extremely rare in young children, at this 
age diffuse or focal hyperinsulinism is more common. Insulinomas may occur sporadically, 
but familial form as a part of MEN 1 should be considered. Exclusion of parathyroid, 
pituitary and pancreatic hormone overproduction should be done in insulinoma patient and 
in family. MEN 1 may be confirmed by analysis of  mutations of gene, encoding menin 
(Greenberg et al, 2000). Routine imaging of the pancreas (abdominal ultrasound, CT, MRI) 
often fails to reveal the tumor, unless it is bigger than 2 cm. Insulinomas are usually 
unvisible on octreotid scan. Elaborating noninvasive diagnostic methods, the endoscopic 
ultrasonography seems to be the most helpful before surgery, higher sensitivity (90%) is 
described only in intraoperative ultrasonographic investigation. In adolescents and adults, 
invasive pancreatic arterial stimulation with calcium and subsequent venous sampling of 
insulin levels may localize the insulinoma to a region of  pancreas, method is technically 
difficult in small children. Accurate diagnosis of hyperinsulinism must precede all invasive 
examinations and surgery (Hirshberg et al, 2000). Factitious hyperinsulinism ought to be 
strictly excluded, especially in puberty and adolescence. Inspite of true hyperinsulinism, C-
peptide level is low in the case of intoxication with human insulin. However, both true 
hyperinsulinism and sulfonylurea poisoning show high C-peptide concentration. If 
iatrogenic hyperinsulinism is suspected, the concentration of sulfonylurea drugs should be 
measured by specific toxicologic examination (Marks &  Teale, 1999). Small number of 
children and adults may suffer from hypoglycemic seizures or syncope due to 
hyperinsulinism occurring with anaerobic exercise. The condition is inherited in an 
autosomal dominant pattern (Meissner et al, 2001). 
4.3 Counter-regulatory hormone deficiency 
Four hormones are involved in maintaining blood glucose level, but only cortisol and 
growth hormone deficiency are usually examined as a cause of hypoglycemia. Although all 
forms of hypocorticism may present by hypoglycemia, ACTH deficiency or 
unresponsiveness is more likely reflected in clinical sign of hypoglycemia than primary 
adrenal failure. Iatrogenic suppression of adrenal function is one of the most common 
causes of ACTH deficiency, but may be underdiagnosed due to absence of typical electrolyte 
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abnormalities. Vomiting, hypotension and hypoglycemia can be provoked by a stressful 
event in a child who weaned high-dose glucocorticoid therapy. Milder clinical manifestation 
may be caused by topical, inhaled or intranasal glucocorticoid preparations. Such treatment 
is advocated for many persons, and combination of these forms may lead to episodic 
hypoglycemia and can have possible impact to growth in childhood (Pinney et al, 2007). 
ACTH deficiency should be excluded in obese patient with red hair, especially before 
planned surgery. POMC mutations has been indentified as a cause of hypocorticism in this 
atypical clinical presentation (Krude et al, 1998). Idiopathic ACTH deficiency can be 
acquired in childhood, adolescence and also later in life. An association with autoimmune 
thyroiditis or celiac disease suggests autoimmune hypophysitis. Detailed history and 
examination are recommended to exclude pituitary damage, e.g. head trauma, pituitary 
infarction, infection, cranial radiation and tumors.  
Patients with primary adrenal insufficiency are hyperpigmented due to oversecretion of  
proopiomelanocortin (POMC) and subsequently high ACTH and MSH levels, hypoglycemia 
is usually associated with typical mineral disturbances. In adolescence and adulthood, the 
common cause is autoimmune adrenalitis. Other autoimmune disorders should be 
considered (as a part of APS1 or APS2a), the positivity of organ-specific antibodies (ACA, 
anti-21-hydroxylase) is helpful in diagnostic approach. Typically, hypoparathyroidism and 
mucocutaneous candidosis precede adrenal failure in child with autoimmune polyglandular 
syndrome type 1 (APS1), defect in autoimmune regulator gene (AIRE) has been determined 
with recessive inheritance. In boys with proven adrenal failure, adrenoleukodystrophy 
should be excluded. This X-linked recessive disorder is detected by high levels of very long-
chain fatty acids in urine. Milder form - adrenomyelopathy develops in childhood and 
adolescence, and neurological disease follows 10-15 years later. Severe form is much rare 
and starts in infancy. Hyperpigmentation and high ACTH level are also found in ACTH 
resistance (Allgrove syndrome – tripple A), inherited autosomal dominantly. Main features 
are achalasia, alacrimia and adrenal failure, patients suffer from autonomic dysfunction and 
progressive neurological symptoms. Mutation in ALADIN gene has been found in patients 
with tripple A syndrome (Randell et al, 2007). 
GH deficiency may be either isolated, or as a part of panhypopituitarism. Two stimulation 
tests (GH<10 ng/ml) are required for diagnosis in children with growth retardation (SDS<-2), 
hypothyroidism and celiac disease should be excluded before testing. One test may be 
sufficient in the case of positive history to cranial radiation, or MRI imaging of empty sella, 
septooptic dysplasia or corporus callosum agenesis. After head surgery due to 
craniopharyngeoma, observing period without GH therapy is 2 years at least. In the case of 
complete pituitary insufficiency, the significant growth rate slowing, low IGF1 level and 
previously claimed three hormone deficiencies, any testing is not necessary. Moreover, 
provocation of hypoglycemia may be harmful and dangerous due to lack of two counter-
regulatory hormones in panhypopituitaric child. Imaging findings, such as agenesis of 
corpus callosum, septooptic dysplasia or empty sella must increase clinical suspicion 
(Rosenfeld & Cohen, 2008).  
Thirty minutes after hypoglycemia, sampling of hormones may reveal counter-regulatory 
deficiency more sensitively than measurement of critical sample. At the time of low blood 
glucose level, higher concentrations of cortisol (>500 nmol/l) and GH (>10 ng/ml) exclude 
substantial lack of these hormones. However, decreased counter-regulatory hormones in 
critical sample are not diagnostic for hormonal deficiencies. The peak of these hormones is 
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present approximately 30 minutes after hypoglycemic episode confirmed by laboratory 
blood glucose measurement below diagnostic threshold (<2,8 mmol/l). Such information 
about duration of hypoglycemia can not be usually obtained at the time of critical sampling. 
On the other hand, measurement of insulin and C-peptide levels at the time of low blood 
glucose level remains crucial for diagnosis of hyperinsulinism.   
Teoretically, epinephrine deficiency may contribute to hypoglycemia of adrenal failure. 
However, hypoglycemia is rare in patients with bilateral adrenalectomy on adequate 
glucocorticoid replacement. Similarly, diabetic patients exhibit diminished epinephrine 
secretion more probably due to repeated hypoglycemia. Reduction of insulin-induced 
hypoglycemia can usually restore normal catecholamine response. Impaired glucagon 
secretion also increases the risk of hypoglycemia in patients with type 1 diabetes (Langdon 
et al, 2008). 
4.4 Glycogen storage disease 
Glucose is stored as a glycogen in the liver, muscles, and kidneys. If there is defect in 
formation or breakdown of glycogen, hypoglycamia may take part. In such group of 
metabolic inborn errors, glycogen storage disease (GSD) type 1 (glucose-6-phosphatase 
deficiency) is the most common cause of hypoglycemia. Appart from defect in glycogen 
metabolism, glucose-6-phosphatase deficiency is also essential enzyme for gluconeogenesis. 
Disruption of two metabolic pathways in GSD type 1 leads to significant persistent or 
recurrent hypoglycemia. Fortunately, glucose values within the range 30-50 mg/dl (1,7-2,8 
mmol/l) are usually well tolerated, reflecting the adaptation of the brain to alternative fuel 
sources (lactate). Despite subtle clinical picture at the time of marked hypoglycemia, 
counter-regulatory hormones are elevated appropriately. Consequent promotion of 
glycogenolysis, gluconeogenesis and lipolysis increases lactate, triglycerides and ketones 
level. Clinically, glucose-6-phosphatase deficiency leads to massive glycogen stores and 
progressive hepatomegaly, renal tubular disease and malabsorbtion, later growth 
retardation is common. In addition to recurrent hypoglycemia, there is also lactic acidosis, 
elevated lipid levels and hyperuricemia in children with GSD type 1. Most cases are 
diagnosed in childhood, although sometimes GSD presents as a neonatal hypoglycemia  
Diagnosis is made by enzymatic studies of liver, kidney or intestine biopsy tissue or by 
elaborating specific gene mutations. Availability of mutation analysis has made the need for 
liver biopsy obsolete. Management approach involves continuous nasogastric or 
gastrostomy nocturnal feeding (6-8 mg/kg/min of glucose) and cornstarch supplementation 
(1-2g/kg every 4 hrs). Patients are fed every 2 hrs during the day, and glucose should 
be continuously provided overnight.  
GSD type 3 (amylo-1,6-glucosidase deficiency) exhibits similar laboratory and clinical 
findings, such as hepatomegaly and growth failure, occasionally progressive muscle 
weakness and cardiomyopathy has been recorded. GSD type 6 and 9 (liver phosphorylase 
deficiency) has a comparatively benign course, mild episodes of hypoglycemia are not 
usually associated with lactic acidemia and hyperuricemia. Furthermore, elevated 
transaminase and hyperlipidemia are measured, affected children are investigated for 
hepatomegaly, hypotonia and muscle weakness. Most of these clinical features resolve by 
puberty, although some individuals may have a problem with cardiomyopathy, myopathy 
and renal tubular acidosis. In patient with concomitant liver and muscle involvment, the use 
of low-carbohydrate high-protein diet has been suggested to protect muscle from lack of 
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alanin. Biochemical studies of leucocytes may confirm the diagnosis of GSD, except type 1 
and 0. Glycogen synthase deficiency (GSD 0) is a rare but probably under-diagnosed cause 
of hypoglycemia. Fasting hypoglycemia is ketotic and unlike of other GSD, hepatomegaly is 
not observed. Diagnosis of GSD 0 can be determined by liver biopsy, recently mutation 
analysis of glycogen synthase gene has been available (Weinstein et al, 2006). 
Glycogen accumulation in liver and kidney may be caused by GLUT2 deficiency (also 
known as Fanconi-Bickel syndrome). GLUT2  allows glucose transport across cell membrane 
of β-cells, renal tubule cells and hepatocytes. Except postprandial hyperglycemia due to 
reduced glucose transport on β-cell, clinical and laboratory findings are similar to Gierke 
disease (GSD type 1). Children suffer from fasting hypoglycemia, postprandial 
hyperglycemia, glucosuria, phosphaturia, aminoaciduria and metabolic acidosis. 
Furthermore, hepatomegaly, hypophosphatemic rickets and severe growth retardation can 
be present (Santer et al, 2002). Unlike GULT2 deficiency, GLUT1 is responsible for glucose 
transport across blood-brain barrier. The clinical consequence varies from classic picture of 
developmental encephalopathy with seizures to atypic presentations, e.g. mental 
retardation, intermittent ataxia, choreoatetosis, dystonia and dysartric speech. The diagnosis 
is confirmed by hypoglycorrhachia in cerebrospinal fluid despite normal plasma glucose 
concentration. Recent discovery of this condition may explain previously longtime reported 
positive effect of ketogenic diet in some patients with neurologic defect. The ketogenic diet 
successfully controls the seizures in patients with GLUT1 deficiency, but has smaller effect 
on the cognitive function (Wang et al, 2005).    
4.5 Autoimmune hypoglycemia 
Autoimmune hypoglycemia can result from antibodies directed either against insulin or 
insulin receptor, and may occur in all ages. The hypoglycemia is most often postprandial, but 
may be fasting. Laboratory findings are usually similar to exogeneous hyperinsulinism (high 
insulin and low C-peptide) in patients with anti-insulin antibodies positivity, whereas 
autoimmune hypoglycemia due to anti-insulin receptor antibodies shows typically 
undetectable insulin and C-peptide level. Rarely, antibodies directed against surface antigens 
on β-cells has been reported as a cause of autoimmune hypoglycemia (Redmon & Nutal, 1999). 
4.6 Reactive hypoglycemia 
The term of idiopathic postprandial syndrome, also known as reactive hypoglycemia, has 
been used for any clinical symptoms suggesting hypoglycemia that occur 2-4 hours after 
meal. Many healthy children and adults may have glycemia less than 60 mg/dl (3,3 
mmol/l) without clinical presentation postpradially, consequently the oral glucose tolerance 
test has as a little diagnostic value in this syndrome. Most patients are adolescent girls with 
positive family history of similar symptoms in mother. At first, diagnosis such as panic 
attack, hyperventilation, vasovagal syncope and orthostatic hypotension should be 
excluded. Diagnosis of reactive hypoglycemia requires confirmation of low blood glucose 
level at the time of clinical symptoms suggesting hypoglycemia, and exclusion of other 
pathologic conditions (e.g. hyperinsulinism).  
4.7 Alimentary hypoglycemia 
All patients with Nissen fundoplication and gastrostomy tube are at risk of alimentary 
hypoglycemia. After surgery, rapid absorbtion of high-glucose fluids causes 
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hyperinsulinism, responsible for hypoglycemia in 1-2 hours later. This condition, known as 
a late (glucose) dumping may occur in one third of patients with fundoplication and gastric 
tube. In long-term management, an avoidance high load of rapid carbohydrates, a 
supplementation of acarbose of 12-75 mg per dose, and a complex carbohydrate formula 
may be successful (Ng et al, 2002). 
4.8 Hypoglycemia induced by exogenous agents 
Many medicaments may cause hypoglycemia as a side effect, directly or indirectly. Unlike 
to direct effect of β-blockers, discontinuation of chronic high-dose inhaled corticosteroid 
treatment and subsequent adrenal suppression might cause hypoglycemia indirectly. The 
correct attitude to any person presenting with hypoglycemia is awareness of detailed drug 
history concerning all family members. Common causes of low blood glucose level due to 
poisoning are paracetamol or salicylate overdoses, sulfonylurea ingestion and insulin 
administration. Especially, insulin overdoses should be considered, if insulin concentration 
is too high despite of supressed C-peptide level. In such patients, family history is usually 
positive for type 1 diabetes treated by human insulins. Administration of insulin analogues 
may not be detected by immunoassay, the serum insulin concentration may be falsely low. 
Recommended treatment is glucose ingestion or infusion, in case of insufficiency of these 
procedures, the successful use of diazoxide and ocreotid has been reported (Lheurex et al, 
2005). Sometimes, antidotes are necessary, for example, paracetamol poisoning requires 
addition of N-acetylcysteine. Similarly, salicylate intoxication may initiate changes in 
glucose metabolism, hyper- and hypoglycemia have been reported. Alcohol consumption 
reduces gluconeogenesis, hypoglycemia may occur in a several hours after acute 
intoxication. Ingestion of plants such as cocklebur (Xanthium stumarium) can cause 
hypoglycemia, kidney or liver dysfunction, and large amount may lead to multi-organ 
failure (Randell, 2007).  
4.9 Hypoglycemia in non-insulin secreting tumors   
Hypoglycemia has been reported in patients with non-insulin secreting tumors, 
predominantly large retroperitoneal ones. The serum evaluation of such patients shows 
elevated insulin–like growth factor 2 (IGF2).  IGF-2 activates IGF-1 receptor and cross 
activates insulin receptor, causing hypoglycemia. In management approach, the method of 
choice is surgical removal of tumor. Some authors reffers to success with growth hormone 
treatment up to the time of definitive surgery (Agus et al, 1995). However, this approach 
may be contradictory and needs other evidence.  
4.10 Hypoglycemia in critical illness and organ failure 
Approximately 30% of patients with severe malaria suffer from hypoglycemia, and the 
presence of low blood glucose seems to be associated with increased mortality in malaric 
patients. In addition, the therapy for malaria can contribute to hypoglycemia, in particular, 
quinine stimulates insulin secretion. Hypoglycemia is also common in other critically ill 
patients and has been reported in organ failure or severe disease, such as sepsis, head injury, 
heart failure, chronic renal failure, acute hepatic necrosis, pancreatitis, severe enteritis and 
multiple organ failure. Etiopathogenesis of hypoglycemia in these patients is often 
multifactorial: lack of substrate, undernutrition, accelerated glucose consumption, impaired 
gluconeogenesis, misplaced infusion line, cytokine and drug effect (Langdon et al, 2008). On 
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the other hand, an acute illness may reveal latent disorder of glucose metabolism (Weinstein 
et al, 2001). 
4.11 Hypoglycemia in diabetes mellitus 
In diabetic patients, clinical symptoms suggesting hypoglycemia should be promptly 
treated by rapid carbohydrate intake, 15 g of carbohydrates are recommended to 50 kg 
patient as usual. If signs last in 15 minutes, the same dose of carbohydrates should be 
taken. Clinical presentation of severe hypoglycemia, such as seizures and 
unconsciousness, must be cured by intramuscular or subcutaneous administration of 
glucagon with assistance of another person. The incidence of hypoglycemia induced by 
insulin therapy is higher than those caused by sulfonylureas. However, pre-existing renal 
failure may increase the risk of hypoglycemia in patients on sulfonyurea therapy. 
Measurements of a particularly low HbA1c level should be suspected of unknown 
hypoglycemic episodes in past. 
The frequency of severe hypoglycemia is declining due to improvement of techniques, 
therapeutic strategies and insulin structure (Baunduceau et al, 2010).  Hypoglycemia may be 
harmful in patients with history of ischemic heart disease, association between severe 
hypoglycemia and sudden death has been described. Prolonged duration of type 1 diabetes 
is linked to higher risk of severe hypoglycemia due to profound lack of insulin, furthermore, 
protective hormone response may be diminished (Heller, 2010). In ADVANCE study, an 
increase in the frequency of severe hypoglycemia was found in elderly diabetics presenting 
with substantial cognitive disorders. However, dementia alone is a significant risk factor for 
occurrence of severe hypoglycemic episodes due to mistakes in diabetes management 
(Bauduceau, 2010). Similarly, infants and small children are not able to manage own 
diabetes, hypoglycemia must be resolved by help of another person, so all hypoglycemia in 
such patients should be considered as a serious.  
During exercise, diabetic patients are usually at risk of glucose declining, sometimes falling 
to hypoglycemic levels. Adequate carbohydrate replacement during and after exercise 
seems to be the most important measure to prevent hypoglycemia, an insulin reduction 
from 20 to 30% can be reasonable only for exercise lasting more than one hour (Grimm et al, 
2004).  Repeated unexpected low blood glucose levels in type 1 diabetes (DM 1) may be the 
indicator of associated disorders. All patients with DM 1 requiring significant reduction of 
insulin dose, should be testing for autoimmune hypothyroidism, hypocorticism and celiac 
disease. 
5. Conclusion 
Diagnostic approach to hypoglycemia should be based on critical sample of intermediate 
metabolites and hormones at the time of laboratory proven low blood glucose level as well 
as 30 minutes after hypoglycemic episode. Authors suggest that repeating second sampling 
may be more helpful for determination of  deficiency of counter-regulatory hormones. All 
management effort should be done to obtain such measurement as soon as possible, with 
consequent quick and appropriate treatment. Delayed or incorrect diagnosis of 
hypoglycemic symptoms may lead to many different irreversibile neurologic disturbances, 
especially in infants and small children.     
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